Subscribe Sign In

Why register?

Home
News
Events
- Find an event
- Live event coverage
Deep Dive
Sales and marketing
Digital
Market Access
Oncology
Patients
R&D
Spotlight On
- Frontiers Health 2022
- The Future of Generics
Advertise

Search

Search

Close

Trending

As Apple Rolls Out Medication Tracking to all iPhones, Pharma Must Embrace Connectivity

AZ and Ionis’ PCSK9 cholesterol drug will not move to phase 3

Curebase & Meru Health unite for app-based mental health trial

Routine NHS access to Ibrance assured with new NICE guidance

Frontiers Health Steering Committee spotlight: Tony Estrella

Capstan Therapeutics

Preparing for an influx of cell and gene therapy approvals

News/ News/ Press Releases/ R&D

CapstanTx secures $165 million to deliver precise in vivo cell engineering

Nicole Raleigh Capstan Therapeutics, CAR-T therapy, cell therapy, in vivo, investment, Lipid Nanoparticles, mRNA, pharma, tLNP 0 Comment

Yesterday, the biotechnology company Capstan Therapeutics launched with $165 million in seed and Series A funding for it

X

CapstanTx secures $165 million to deliver precise in vivo cell engineering

https://pharmaphorum.com/news/capstantx-secures-165-million-to-deliver-precise-in-vivo-cell-engineering/

Get in-depth news, opinions and features on pharma and healthcare sent straight to your inbox

Featured content

How to improve payer engagement with tailored value communication

How to improve payer engagement with tailored value communication

How will NICE fare in a post-Brexit world?

How will NICE fare in a post-Brexit world?

Events

MAPS 2018 EMEA Annual Meeting

MAPS 2018 EMEA Annual Meeting

Cell & Gene Therapy 2018

Cell & Gene Therapy 2018

Patient Engagement Event - a real world snapshot, beyond the talk

Patient Engagement Event - a real world snapshot, beyond the talk

Most popular

Most Viewed

Biogen trumpets data from ALS trial as FDA decision looms
Revamped Novartis highlights top R&D programmes at management update
First human data backs Calibr/AbbVie's "switchable" CAR-T therapy
AZ and Ionis' PCSK9 cholesterol drug will not move to phase 3
NICE says yes to BeiGene's Brukinsa after Scottish nay

Tweets from @pharmaphorum

Tweets by @pharmaphorum

Advertise

Contribute
Work for pharmaphorum

About us
Contact us
Privacy policy
Terms & conditions
Cookie Policy

The rights of trade mark owners are acknowledged. pharmaphorum media limited

Website and content copyright © 2009-, pharmaphorum media limited or its licensors; all rights reserved.

© 2022

Powered by WordPress • Themify WordPress Themes

Login

Username or Email Address

Password

Remember Me

Lost your password?

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com